Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SAT1 | P21673 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18230693 | 1.00 | CYP2C19 (0.40) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL19971131 | 0.91 | KDM1A (0.46) | CYP2C19MEN1GLAKMT2AKDM1A | |
| SCHEMBL13380623 | 0.91 | KDM1A (0.46) | CYP2C19MEN1GLAKMT2AKDM1A | |
| SCHEMBL22068794 | 0.89 | KDM1A (0.44) | KDM1AEPHX1 | |
| SCHEMBL20185703 | 0.89 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL18230728 | 0.89 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL22068805 | 0.89 | EPHX1 (0.37) | KDM1AEPHX1 | |
| SCHEMBL20185667 | 0.88 | KDM1A (0.43) | KDM1AEPHX1 | |
| SCHEMBL20185675 | 0.86 | EPHX1 (0.41) | KDM1AEPHX1 | |
| SCHEMBL22068787 | 0.85 | EPHX1 (0.41) | KDM1AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113265053-A | Catalyst having polysiloxane structural units for curable compositions | SIKA技术股份公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-108473815-B | Catalyst having polysiloxane structural units for curable compositions | SIKA技术股份公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3795649-A2 | CATALYST WITH POLYSILOXANE STRUCTURE UNIT FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-3294803-B1 | GUANIDINE GROUP CONTAINING CATALYST | SIKA TECH AG (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10836868-B2 | Catalyst having a polysiloxane structural unit for hardenable compositions | SIKA TECHNOLOGY AG (CH) | 2020-11-17 | — | — | US | disclosed |
| CN-107735438-B | Guanidino-containing catalysts | SIKA技术股份公司 | 2020-06-09 | — | — | CN | disclosed |
| US-10414875-B2 | Catalyst containing guanidine groups | SIKA TECHNOLOGY AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-20180327549-A1 | CATALYST HAVING A POLYSILOXANE STRUCTURAL UNIT FOR HARDENABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2018-11-15 | — | — | US | disclosed |
| EP-3390552-A1 | CATALYST HAVING A POLYSILOXANE STRUCTURAL UNIT FOR HARDENABLE COMPOSITIONS | Sika Technology AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-05-31 | — | — | US | disclosed |
| EP-3294803-A1 | CATALYST CONTAINING GUANIDINE GROUPS | Sika Technology AG (CH) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414875-B2 | Catalyst containing guanidine groups | GMPS, GMNN, RNMT | CYP2C19 1437/4885MEN1 2485/4885GLA 417/4885 |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | GMPS, RNMT, GMNN | CYP2C19 1698/4885MEN1 2446/4885GLA 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.